Ambisome
Total Payments
$351,770
Transactions
218
Doctors
130
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $781.89 | 15 | 11 |
| 2021 | $199,416 | 2 | 0 |
| 2019 | $106,374 | 1 | 0 |
| 2017 | $45,198 | 200 | 119 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $306,356 | 4 | 87.1% |
| Space rental or facility fees (teaching hospital only) | $42,000 | 21 | 11.9% |
| Food and Beverage | $3,414 | 193 | 1.0% |
Payments by Type
Research
$306,356
4 transactions
General
$45,414
214 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Cryptococcal Infections in Non -HIV Infected Hosts: A Prospective International Study (MSG-11) | Gilead Sciences, Inc. | $287,790 | 0 |
| Short Courses of Liposomal Amphotericin B Induction Therapy for Talaromyces marneffei infection (LAmB-Tm) | Gilead Sciences, Inc. | $18,000 | 0 |
| Direct and Immune Cell-Mediated Synergism of Isavuconazole and Micafungin Against Echinocandin-Resistant Candida Glabrata, Echinocandin-Resistant Candida Auris, and Azole-Resistant Aspergillus Fumigatus | Astellas US Technologies | $566.10 | 0 |
Top Doctors Receiving Payments for Ambisome — Page 6
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Critical Care Medicine | Bourbonnais, IL | $11.00 | 1 |
| , MD | Pulmonary Disease | Kankakee, IL | $11.00 | 1 |
| , MD | Critical Care Medicine | Kankakee, IL | $11.00 | 1 |
| , MD | Internal Medicine | Elizabethtown, KY | $10.84 | 1 |
| , M.D | Specialist | Columbia, MD | $10.36 | 1 |
| , DO | Hematology & Oncology | Gilbert, AZ | $10.33 | 1 |
Ad
Manufacturing Companies
- Gilead Sciences, Inc. $305,790
- Astellas Pharma US Inc $45,364
- Astellas US Technologies $566.10
- Astellas Pharma Global Development $50.10
Product Information
- Type Drug
- Total Payments $351,770
- Total Doctors 130
- Transactions 218
About Ambisome
Ambisome is a drug associated with $351,770 in payments to 130 healthcare providers, recorded across 218 transactions in the CMS Open Payments database. The primary manufacturer is Gilead Sciences, Inc..
Payment data is available from 2017 to 2022. In 2022, $781.89 was paid across 15 transactions to 11 doctors.
The most common payment nature for Ambisome is "Unspecified" ($306,356, 87.1% of total).
Ambisome is associated with 3 research studies, including "Cryptococcal Infections in Non -HIV Infected Hosts: A Prospective International Study (MSG-11)" ($287,790).